echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The FDA awarded TK216 the "Rare Pediatric Disease Title" for the treatment of Ewing sarcoma.

    The FDA awarded TK216 the "Rare Pediatric Disease Title" for the treatment of Ewing sarcoma.

    • Last Update: 2020-10-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Ewing sarcoma is a primitive cell in the bone marrow, first reported by American pathologist James Ewing in 1921.
    Food and Drug Administration (FDA) has awarded TK216 the "rare pediatric disease title" for the treatment of Ewing sarcoma, the company's biopharmaceutical company, Oncternal Therapeutics, announced today.
    TK216 is a small molecular inhibitor that targets the E26 conversion-specific (ETS) cancer protein family.
    "rare pediatric disease" is defined as a serious or life-threatening pediatric disease that affects fewer than 200,000 people in the United States.
    if the FDA approves TK216 for the treatment of Ewing sarcoma, Oncternal may be eligible for a priority review certificate.
    if this voucher is issued, it can be redeemed for priority review of subsequent marketing applications or sold or transferred to other sponsors.
    . James Breitmeyer, President and CEO of Oncternal, said, "Ewing sarcoma is a devastating cancer with a high demand for medical care.
    are currently recruiting patients with relapsed/resusctic Ewing sarcoma to participate in clinical trials of TK216, and we hope to provide data on ongoing Phase I clinical trials in the fourth quarter of 2020."
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.